NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Price Target & More

$5.12 +0.07 (+1.39 %)
(As of 04/23/2018 01:00 PM ET)
Previous Close$5.05
Today's Range$5.00 - $5.20
52-Week Range$2.10 - $5.80
Volume47,566 shs
Average Volume73,449 shs
Market Capitalization$71.57 million
P/E RatioN/A
Dividend YieldN/A
Beta0.74

About Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Debt-to-Equity Ratio0.17%
Current Ratio10.98%
Quick Ratio10.99%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$310,000.00
Price / Sales234.03
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book2.56

Profitability

EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-65.72%
Return on Assets-59.20%

Miscellaneous

Employees81
Outstanding Shares14,170,000

How to Become a New Pot Stock Millionaire

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.34. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $6.38 million. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 65.72%. View Xenon Pharmaceuticals' Earnings History.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Xenon Pharmaceuticals.

What price target have analysts set for XENE?

3 brokers have issued 1 year price objectives for Xenon Pharmaceuticals' stock. Their predictions range from $5.00 to $9.00. On average, they expect Xenon Pharmaceuticals' share price to reach $6.6667 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.

Who are some of Xenon Pharmaceuticals' key competitors?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the folowing people:
  • Michael M. Tarnow, Chairman of the Board (Age 71)
  • Ian C. Mortimer CPA, President, Chief Financial Officer, Chief Operating Officer (Age 42)
  • Simon Neil Pimstone Ph.D., Chief Executive Officer, Director (Age 48)
  • James R. Empfield, Senior Vice President - Drug Discovery
  • Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development (Age 54)
  • Charles M. Cohen Ph.D., Vice President - Biology (Age 66)
  • Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development (Age 55)
  • Karen G. Corraini J.D., General Counsel and Corporate Secretary (Age 60)
  • Mohammad Azab, Director (Age 59)
  • Steven R Gannon, Director (Age 55)

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News headlines about XENE stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a news sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $5.15.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $71.57 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]


MarketBeat Community Rating for Xenon Pharmaceuticals (XENE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Xenon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 30.21%. The high price target for XENE is $9.00 and the low price target for XENE is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.6667$6.6667$5.00$8.1667
Price Target Upside: 30.21% upside36.05% upside66.67% upside172.22% upside

Xenon Pharmaceuticals (NASDAQ:XENE) Consensus Price Target History

Price Target History for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018Jefferies GroupBoost Price TargetBuy$6.00MediumView Rating Details
3/8/2018Stifel NicolausBoost Price TargetBuy -> Buy$7.00 -> $9.00HighView Rating Details
6/27/2017Canaccord GenuityReiterated RatingBuy$5.00LowView Rating Details
12/22/2016Bloom BurtonInitiated CoverageBuy$14.50N/AView Rating Details
9/26/2016GuggenheimInitiated CoverageBuy -> Buy$20.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Xenon Pharmaceuticals (NASDAQ:XENE) Earnings History and Estimates Chart

Earnings by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.49)($0.49)($0.49)
Q2 20181($0.51)($0.51)($0.51)
Q3 20181($0.54)($0.54)($0.54)
Q4 20181$0.19$0.19$0.19

Xenon Pharmaceuticals (NASDAQ XENE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
3/7/2018After Market($0.11)($0.45)$6.38 million$0.02 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.08)($0.43)$6.52 million$0.26 millionViewN/AView Earnings Details
8/3/20176/30/2017($0.38)($0.41)$0.38 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.35)($0.43)$0.45 million$0.02 millionViewN/AView Earnings Details
3/8/201712/31/2016($0.42)($0.32)$0.40 million$0.38 millionViewListenView Earnings Details
11/3/2016Q316($0.43)($0.51)$0.40 million$0.41 millionViewListenView Earnings Details
8/3/2016Q216($0.48)($0.42)$0.50 million$0.41 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 million$0.60 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.90 million$3.23 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.90 million$4.05 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57$5.10 million$4.43 millionViewListenView Earnings Details
12/15/2014$0.41$1.69$5.00 million$13.19 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Xenon Pharmaceuticals (NASDAQ:XENE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 64.64%
Insider Trading History for Xenon Pharmaceuticals (NASDAQ:XENE)
Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2017Mohammad AzabDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/22/2017Mohammad AzabDirectorBuy10,000$2.95$29,500.0021,210View SEC Filing  
8/18/2017Mohammad AzabDirectorBuy6,335$2.90$18,371.5012,898View SEC Filing  
8/18/2017Raymond WinquistInsiderBuy1,000$3.00$3,000.001,000View SEC Filing  
8/15/2017Bvf Partners L P/IlMajor ShareholderBuy18,858$2.41$45,447.78View SEC Filing  
8/15/2017James R EmpfieldSVPBuy10,000$2.48$24,800.0010,000View SEC Filing  
8/15/2017Value Fund L P BiotechnologyInsiderBuy60,202$2.61$157,127.22View SEC Filing  
8/14/2017Bvf Partners L P/IlMajor ShareholderBuy41,344$2.70$111,628.80View SEC Filing  
8/14/2017Michael R HaydenDirectorBuy15,000$2.75$41,250.00161,187View SEC Filing  
8/11/2017Steven GannonDirectorBuy15,000$2.82$42,300.0015,000View SEC Filing  
8/10/2017Ian MortimerCFOBuy15,000$2.88$43,200.006,000View SEC Filing  
8/10/2017Richard H SchellerDirectorBuy7,000$2.85$19,950.007,000View SEC Filing  
8/10/2017Simon N PimstoneCEOBuy6,000$2.90$17,400.00217,847View SEC Filing  
8/8/2017Gary PatouDirectorBuy5,000$3.00$15,000.0012,028View SEC Filing  
6/27/2017Value Fund L P BiotechnologyInsiderBuy85,461$4.00$341,844.00View SEC Filing  
6/22/2017Value Fund L P BiotechnologyInsiderBuy20,411$4.00$81,644.00View SEC Filing  
6/19/2017Value Fund L P BiotechnologyInsiderBuy26,408$3.84$101,406.72View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy358,698$3.81$1,366,639.38View SEC Filing  
12/15/2016Frank A HollerDirectorSell30,000$7.85$235,500.00115,869View SEC Filing  
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70145,869View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66169,006View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.001,000View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.126,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Xenon Pharmaceuticals (NASDAQ XENE) News Headlines

Source:
DateHeadline
Xenon Pharmaceuticals (XENE) Receives "Buy" Rating from Canaccord GenuityXenon Pharmaceuticals (XENE) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - April 20 at 3:00 PM
 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Post Quarterly Sales of $100,000.00 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Post Quarterly Sales of $100,000.00
www.americanbankingnews.com - April 14 at 1:49 AM
Xenon Pharmaceuticals Inc. (XENE) Expected to Post Earnings of -$0.48 Per ShareXenon Pharmaceuticals Inc. (XENE) Expected to Post Earnings of -$0.48 Per Share
www.americanbankingnews.com - April 12 at 11:14 PM
Xenon Pharmaceuticals (XENE) Lifted to "Hold" at ValuEngineXenon Pharmaceuticals (XENE) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange ...Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange ...
globenewswire.com - March 30 at 5:29 PM
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
finance.yahoo.com - March 28 at 5:17 PM
Zacks: Analysts Anticipate Xenon Pharmaceuticals Inc (XENE) Will Announce Earnings of -$0.48 Per ShareZacks: Analysts Anticipate Xenon Pharmaceuticals Inc (XENE) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - March 26 at 11:08 PM
Jefferies Group Raises Xenon Pharmaceuticals (XENE) Price Target to $6.00Jefferies Group Raises Xenon Pharmaceuticals (XENE) Price Target to $6.00
www.americanbankingnews.com - March 22 at 3:02 PM
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer - GlobeNewswire (press release)Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:35 AM
Xenon Pharmaceuticals (XENE) Names Dr. Ernesto Aycardi as Chief Medical OfficerXenon Pharmaceuticals (XENE) Names Dr. Ernesto Aycardi as Chief Medical Officer
www.streetinsider.com - March 13 at 7:15 PM
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical OfficerDr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer
finance.yahoo.com - March 13 at 7:15 PM
Xenon Pharmaceuticals Inc (XENE) Forecasted to Earn Q1 2018 Earnings of ($0.49) Per ShareXenon Pharmaceuticals Inc (XENE) Forecasted to Earn Q1 2018 Earnings of ($0.49) Per Share
www.americanbankingnews.com - March 12 at 1:17 AM
Xenon Pharmaceuticals (XENE) Downgraded by ValuEngine to SellXenon Pharmaceuticals (XENE) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 11 at 7:10 PM
Stifel Nicolaus Increases Xenon Pharmaceuticals (XENE) Price Target to $9.00Stifel Nicolaus Increases Xenon Pharmaceuticals (XENE) Price Target to $9.00
www.americanbankingnews.com - March 11 at 10:28 AM
Zacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) to Announce -$0.47 Earnings Per ShareZacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) to Announce -$0.47 Earnings Per Share
www.americanbankingnews.com - March 9 at 5:18 PM
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:21 AM
Xenon Pharmaceuticals (XENE) Releases  Earnings ResultsXenon Pharmaceuticals (XENE) Releases Earnings Results
www.americanbankingnews.com - March 8 at 10:29 AM
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 7 at 6:33 PM
Xenon Pharmaceuticals Inc. to Host Earnings CallXenon Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:33 PM
Xenon Pharmaceuticals Q4 Earnings OutlookXenon Pharmaceuticals Q4 Earnings Outlook
finance.yahoo.com - March 7 at 6:33 PM
Xenon Pharmaceuticals (XENE) Rating Increased to Hold at ValuEngineXenon Pharmaceuticals (XENE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 1 at 11:30 PM
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - February 28 at 6:02 PM
Xenon Pharmaceuticals (XENE) Raised to "Hold" at Zacks Investment ResearchXenon Pharmaceuticals (XENE) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 28 at 3:45 PM
Xenon Pharmaceuticals (XENE) Set to Announce Earnings on TuesdayXenon Pharmaceuticals (XENE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM
Xenon Pharmaceuticals Inc (XENE) Expected to Post Quarterly Sales of $6.38 MillionXenon Pharmaceuticals Inc (XENE) Expected to Post Quarterly Sales of $6.38 Million
www.americanbankingnews.com - February 22 at 4:32 AM
-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter-$0.11 EPS Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - February 20 at 11:14 PM
BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical TrialBRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial
www.reuters.com - February 20 at 5:45 PM
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical TrialXenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
finance.yahoo.com - February 20 at 5:45 PM
Xenon Pharmaceuticals (XENE) Upgraded at ValuEngineXenon Pharmaceuticals (XENE) Upgraded at ValuEngine
www.americanbankingnews.com - February 4 at 10:14 AM
Head to Head Review: Xenon Pharmaceuticals (XENE) & Bioverativ (BIVV)Head to Head Review: Xenon Pharmaceuticals (XENE) & Bioverativ (BIVV)
www.americanbankingnews.com - February 3 at 11:18 PM
Xenon Pharmaceuticals (XENE) Stock Rating Upgraded by Zacks Investment ResearchXenon Pharmaceuticals (XENE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 21 at 6:34 AM
Zacks: Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Post Quarterly Sales of $6.38 MillionZacks: Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Post Quarterly Sales of $6.38 Million
www.americanbankingnews.com - January 20 at 6:28 PM
Xenon Pharmaceuticals Inc (XENE) Expected to Post Earnings of -$0.11 Per ShareXenon Pharmaceuticals Inc (XENE) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - January 18 at 1:42 AM
Xenon Pharmaceuticals Outlines Key Milestones for 2018Xenon Pharmaceuticals Outlines Key Milestones for 2018
finance.yahoo.com - January 8 at 10:41 AM
$6.38 Million in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter$6.38 Million in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - January 3 at 3:00 PM
 Analysts Expect Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million Analysts Expect Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million
www.americanbankingnews.com - December 17 at 8:48 AM
 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Earnings of -$0.11 Per Share Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - December 15 at 1:34 PM
Xenon Pharmaceuticals (XENE) Says Positive Preclinical Data from its XEN901 Epilepsy Program to be Presented at AESXenon Pharmaceuticals (XENE) Says Positive Preclinical Data from its XEN901 Epilepsy Program to be Presented at AES
www.streetinsider.com - December 6 at 10:47 AM
Xenon Pharmaceuticals (XENE) Says Positive Preclinical Data from ... - StreetInsider.comXenon Pharmaceuticals (XENE) Says Positive Preclinical Data from ... - StreetInsider.com
www.streetinsider.com - December 5 at 12:14 PM
Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual MeetingPositive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting
finance.yahoo.com - December 4 at 4:26 PM
 Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) Will Announce Quarterly Sales of $6.38 Million
www.americanbankingnews.com - November 29 at 11:56 AM
Appili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its BoardAppili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its Board
www.businesswire.com - November 28 at 11:34 AM
Head to Head Review: Ardelyx (ARDX) & Xenon Pharmaceuticals (XENE)Head to Head Review: Ardelyx (ARDX) & Xenon Pharmaceuticals (XENE)
www.americanbankingnews.com - November 18 at 11:34 PM
Xenon Pharmaceuticals Inc. (XENE) Director Acquires $33,300.00 in StockXenon Pharmaceuticals Inc. (XENE) Director Acquires $33,300.00 in Stock
www.americanbankingnews.com - November 16 at 9:24 PM
FY2017 EPS Estimates for Xenon Pharmaceuticals Inc. (XENE) Lowered by Jefferies GroupFY2017 EPS Estimates for Xenon Pharmaceuticals Inc. (XENE) Lowered by Jefferies Group
www.americanbankingnews.com - November 10 at 12:26 PM
FDA Nod For COLL, INGN Ups View, Positive News Dimmed By Earnings Miss At KERXFDA Nod For COLL, INGN Ups View, Positive News Dimmed By Earnings Miss At KERX
www.rttnews.com - November 9 at 10:18 AM
Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare ConferenceXenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 9 at 10:18 AM
Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 10:18 AM
Jefferies Group Analysts Reduce Earnings Estimates for Xenon Pharmaceuticals Inc. (XENE)Jefferies Group Analysts Reduce Earnings Estimates for Xenon Pharmaceuticals Inc. (XENE)
www.americanbankingnews.com - November 9 at 9:34 AM
Xenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 7:12 PM

SEC Filings

Xenon Pharmaceuticals (NASDAQ:XENE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Xenon Pharmaceuticals (NASDAQ:XENE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Xenon Pharmaceuticals (NASDAQ XENE) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.